Avantor, Inc. AVTR

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
47/100
Developing

About Avantor, Inc.

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, … Full AVTR analysis →

Competitive advantage assessment

Key strengths

  • Stable Gross Margin Profile Gross margin stability is strong (score 0.94). Low volatility confirms durable consumable pricing.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.26). May indicate commodity-like product mix or distributor margin drag.
  • Declining FCF Margin FCF trend score is negative (score 0.31). Declining FCF margin warrants scrutiny of capital allocation discipline.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
53

Where AVTR ranks in Medical Instruments & Supplies

Avantor, Inc. ranks #34 of 62 scored companies in Medical Instruments & Supplies by moat score — the top 55%. The widest moat in the group is Intuitive Surgical, Inc. (ISRG) at 86/100.

Moat scores for companies ranked near AVTR in Medical Instruments & Supplies
# Company Moat score Rating
30 Teleflex Incorporated TFX 54/100 Moderate
31 Repligen Corporation RGEN 53/100 Moderate
32 STAAR Surgical Company STAA 51/100 Moderate
33 ICU Medical, Inc. ICUI 49/100 Developing
34 Avantor, Inc. AVTR 47/100 Developing
35 Nyxoah SA NYXH 45/100 Developing
36 Femasys Inc. FEMY 43/100 Developing
37 DENTSPLY SIRONA Inc. XRAY 43/100 Developing
38 Baxter International Inc. BAX 40/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How AVTR scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 53 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 54 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 47 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 37 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 30 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 54 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding AVTR's moat

What is Avantor, Inc.'s moat score?

Avantor, Inc. (AVTR) scores 47 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #34 of 62 scored companies in Medical Instruments & Supplies, the top 55%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Medical Instruments & Supplies. Its strongest defense is R&D Pipeline & Capital Returns (54/100) and its weakest is Capital Structure & Resilience (30/100).

How does Avantor, Inc. compare with other Medical Instruments & Supplies companies?

Avantor, Inc. ranks #34 of 62 scored companies in Medical Instruments & Supplies by moat score. The widest moat in Medical Instruments & Supplies is Intuitive Surgical, Inc. (ISRG) at 86/100. The companies ranked closest are ICU Medical, Inc. (ICUI) at 49 just above it and Nyxoah SA (NYXH) at 45 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Medical Instruments & Supplies. The defenses are then weighted to produce the overall score out of 100.

Why is Avantor, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Avantor, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and AVTR scores: Pricing Power & Consumable Moat (53), R&D Pipeline & Capital Returns (54), FCF Quality & Cash Conversion (47), Commercial Execution (37), Capital Structure & Resilience (30), Growth Durability (54). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000